Revance Therapeutics (RVNC) Tops Q3 EPS by 25c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.64), $0.25 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand